Trioxaquines: hybrid molecules for the treatment of malaria.

Show simple item record

dc.contributor.author Chauhan, Shikha S
dc.contributor.author Sharma, Moni
dc.contributor.author Chauhan, P M S
dc.date.accessioned 2011-06-24T09:31:41Z
dc.date.available 2011-06-24T09:31:41Z
dc.date.issued 2010
dc.identifier.citation Drug News & Perspective, 23(10), 632-646 en
dc.identifier.uri http://hdl.handle.net/123456789/695
dc.description.abstract Artemisinin, with its 1,2,4-trioxane as active motif, is now the first-line treatment for multidrug-resistant malaria. The endoperoxide ring is essential for the antimalarial activity of artemisinin. Based on its mechanism of action new hybrid molecules, named trioxaquines with dual mode of action has been designed. Trioxaquines are made by the covalent attachment of a trioxane, having alkylating ability, to a quinoline, known to easily penetrate within infected erythrocytes. This review discusses the importance of various hybrid molecules of artemisinin and 4-aminoquinoline in the treatment of malaria and the evolution of trioxaquine hybrid, as a promising antimalarial drug candidate. en
dc.format.extent 1052716 bytes
dc.format.mimetype application/pdf
dc.language.iso en en
dc.relation.ispartofseries CDRI COMMUNICATION NO. 7975 en
dc.subject Antimalarial en
dc.subject Hybrid en
dc.subject 4-aminoquinoline en
dc.subject Artemisinin en
dc.subject Trioxaquine en
dc.title Trioxaquines: hybrid molecules for the treatment of malaria. en
dc.type Article en


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account